An FDA-approved multiple sclerosis drug that requires 2.5 hours for the first infusion and 3.5 hours for subsequent doses might be able to shorten its duration to 10 minutes, its maker said July 14.
In a phase 3 trial of Ocrevus (ocrelizumab), Roche Group's Genentech saw its twice-yearly subcutaneous injection meet primary and secondary endpoints in patients with relapsing forms of MS or primary progressive MS, according to a news release.
The investigative subcutaneous therapy had similar safety and efficacy results as its approved intravenous solution, according to Genentech.
"Detailed results from the trial will be presented at an upcoming medical meeting and submitted to health authorities around the world," the company said.